Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

110 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cancer of the ovary.
Cannistra SA. Cannistra SA. N Engl J Med. 1993 Nov 18;329(21):1550-9. doi: 10.1056/NEJM199311183292108. N Engl J Med. 1993. PMID: 8155119 Review. No abstract available.
Gene-expression profiling in epithelial ovarian cancer.
Konstantinopoulos PA, Spentzos D, Cannistra SA. Konstantinopoulos PA, et al. Among authors: cannistra sa. Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. doi: 10.1038/ncponc1178. Epub 2008 Jul 22. Nat Clin Pract Oncol. 2008. PMID: 18648354 Review.
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Matulonis UA, et al. Among authors: cannistra sa. J Clin Oncol. 2009 Nov 20;27(33):5601-6. doi: 10.1200/JCO.2009.23.2777. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826113 Free PMC article. Clinical Trial.
Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA. Konstantinopoulos PA, et al. Among authors: cannistra sa. Cancer Res. 2011 Aug 1;71(15):5081-9. doi: 10.1158/0008-5472.CAN-10-4668. Epub 2011 Jun 15. Cancer Res. 2011. PMID: 21676886
Advances in the management of epithelial ovarian cancer.
Berkenblit A, Cannistra SA. Berkenblit A, et al. Among authors: cannistra sa. J Reprod Med. 2005 Jun;50(6):426-38. J Reprod Med. 2005. PMID: 16050567 Review.
Cancer of the ovary.
Cannistra SA. Cannistra SA. N Engl J Med. 2004 Dec 9;351(24):2519-29. doi: 10.1056/NEJMra041842. N Engl J Med. 2004. PMID: 15590954 Review. No abstract available.
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA. Berkenblit A, et al. Among authors: cannistra sa. Gynecol Oncol. 2003 Jun;89(3):486-93. doi: 10.1016/s0090-8258(03)00138-0. Gynecol Oncol. 2003. PMID: 12798716 Clinical Trial.
The ethics of early stopping rules: who is protecting whom?
Cannistra SA. Cannistra SA. J Clin Oncol. 2004 May 1;22(9):1542-5. doi: 10.1200/JCO.2004.02.150. J Clin Oncol. 2004. PMID: 15117977 No abstract available.
Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.
Liu JF, Cannistra SA. Liu JF, et al. Among authors: cannistra sa. J Clin Oncol. 2014 May 1;32(13):1287-9. doi: 10.1200/JCO.2013.54.7299. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637996 No abstract available.
Intraperitoneal chemotherapy comes of age.
Cannistra SA. Cannistra SA. N Engl J Med. 2006 Jan 5;354(1):77-9. doi: 10.1056/NEJMe058308. N Engl J Med. 2006. PMID: 16394306 No abstract available.
110 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback